EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, MET
- 100% NPV.
- 100% NPV.
Essential NGS Panel
The AmoyDx® Essential NGS Panel (Reversible Terminator Sequencing), based on Next Generation Sequencing (NGS) technology, is intended for qualitative detection of SNVs, InDels and Fusions in 10 driver genes in DNA extracted from formalin-fixed paraffin-embedded (FFPE) tissue or plasma sample in patients with NSCLC or CRC by converting sample nucleic acids to sequenceable libraries. The test results are for clinical reference only. The clinician should judge the test results based on the patient's condition, drug indications, treatment response and other laboratory test indicators comprehensively.
This kit is developed based on ddCAP technology. Different from normal capture technology, the probes are designed not only for sense strand but also for antisense strand to get better coverage of target region. The Unique Identifier sequences are introduced to both end of each template for tracing back to original template and error correction. With this error correction system, the sensitivity can be down to 0.2%, and applicable for all sample types, including liquid biopsy sample.
To order, please contact email@example.com.
AmoyDx Essential NGS Panel is available in the following size.
|Product Name||Size (test/kit)||Storage||Cat. No.|
|AmoyDx Essential NGS Panel||24T||-20℃||8.06.27401X024I|
1. Xu, Hanyan, et al. "A comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients." Translational lung cancer research 8.2 (2019): 135.
2. Wu, Wei, et al. "Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients." Diagnostic Pathology 15.1 (2020): 1-7.